Which has stronger earnings and valuation, OKYO or ALLR?

OKYO Pharma has higher earnings, but lower revenue than Allarity Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$8.95M N/A N/A Allarity Therapeutics $320K 60.16 -$11.23M -$0.78 N/A

Is OKYO or ALLR more profitable?

OKYO Pharma's return on equity of 0.00% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets OKYO Pharma N/A N/A N/A Allarity Therapeutics N/A -152.77% -46.50%

Is PLRX or ALLR more profitable?

Pliant Therapeutics' return on equity of -52.17% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pliant Therapeutics N/A -52.17% -40.46% Allarity Therapeutics N/A -152.77% -46.50%

Does the media prefer PLRX or ALLR?

In the previous week, Pliant Therapeutics and Pliant Therapeutics both had 2 articles in the media. Pliant Therapeutics' average media sentiment score of 0.26 beat Allarity Therapeutics' score of 0.00 indicating that Pliant Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pliant Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Allarity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer YARW or ALLR?

In the previous week, Yarrow Bioscience had 5 more articles in the media than Allarity Therapeutics. MarketBeat recorded 7 mentions for Yarrow Bioscience and 2 mentions for Allarity Therapeutics. Yarrow Bioscience's average media sentiment score of 0.37 beat Allarity Therapeutics' score of 0.00 indicating that Yarrow Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Yarrow Bioscience 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allarity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ALLR or XBIT more profitable?

XBiotech's return on equity of -31.62% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -152.77% -46.50% XBiotech N/A -31.62% -30.29%

Does the media refer more to ALLR or XBIT?

In the previous week, Allarity Therapeutics had 1 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for Allarity Therapeutics and 1 mentions for XBiotech. Allarity Therapeutics' average media sentiment score of 0.00 equaled XBiotech'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allarity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral XBiotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ALLR or ALPS?

Allarity Therapeutics presently has a consensus target price of $10.25, indicating a potential upside of 747.11%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Allarity Therapeutics is more favorable than ALPS Group Inc Ordinary Share. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ALPS Group Inc Ordinary Share 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALLR or ALPS more profitable?

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -152.77% -46.50% ALPS Group Inc Ordinary Share N/A N/A N/A

Allarity Therapeutics (ALLR) Competitors

$1.21 +0.05 (+4.31%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.20 0.00 (-0.41%)

As of 09/18/2026 07:46 PM Eastern

Compare

ALLR vs. OKYO, PLRX, YARW, XBIT, and ALPS

Should you buy Allarity Therapeutics stock or one of its competitors? Allarity Therapeutics's main competitors and comparable companies include OKYO Pharma (OKYO), Pliant Therapeutics (PLRX), Yarrow Bioscience (YARW), XBiotech (XBIT), and ALPS Group Inc Ordinary Share (ALPS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Allarity Therapeutics compare to OKYO Pharma?

OKYO Pharma (NASDAQ:OKYO) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

OKYO Pharma has a beta of 0.03, suggesting that its stock price is 97% less volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

OKYO Pharma presently has a consensus target price of $5.67, indicating a potential upside of 316.67%. Allarity Therapeutics has a consensus target price of $10.25, indicating a potential upside of 747.11%. Given Allarity Therapeutics' higher possible upside, analysts clearly believe Allarity Therapeutics is more favorable than OKYO Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by company insiders. Comparatively, 0.2% of Allarity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Allarity Therapeutics had 2 more articles in the media than OKYO Pharma. MarketBeat recorded 2 mentions for Allarity Therapeutics and 0 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 0.00 equaled Allarity Therapeutics'average media sentiment score.

Company	Overall Sentiment
OKYO Pharma	Neutral
Allarity Therapeutics	Neutral

OKYO Pharma has higher earnings, but lower revenue than Allarity Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A
Allarity Therapeutics	$320K	60.16	-$11.23M	-$0.78	N/A

OKYO Pharma's return on equity of 0.00% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Allarity Therapeutics	N/A	-152.77%	-46.50%

Summary

OKYO Pharma beats Allarity Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Allarity Therapeutics compare to Pliant Therapeutics?

Pliant Therapeutics (NASDAQ:PLRX) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Pliant Therapeutics and Pliant Therapeutics both had 2 articles in the media. Pliant Therapeutics' average media sentiment score of 0.26 beat Allarity Therapeutics' score of 0.00 indicating that Pliant Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pliant Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allarity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pliant Therapeutics currently has a consensus price target of $3.00, indicating a potential upside of 170.27%. Allarity Therapeutics has a consensus price target of $10.25, indicating a potential upside of 747.11%. Given Allarity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Allarity Therapeutics is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Pliant Therapeutics has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 8.7% of Pliant Therapeutics shares are owned by insiders. Comparatively, 0.2% of Allarity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Pliant Therapeutics' return on equity of -52.17% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-52.17%	-40.46%
Allarity Therapeutics	N/A	-152.77%	-46.50%

Allarity Therapeutics has lower revenue, but higher earnings than Pliant Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	43.50	-$149.34M	-$1.49	N/A
Allarity Therapeutics	$320K	60.16	-$11.23M	-$0.78	N/A

Summary

Pliant Therapeutics beats Allarity Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Allarity Therapeutics compare to Yarrow Bioscience?

Yarrow Bioscience (NASDAQ:YARW) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Allarity Therapeutics has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Yarrow Bioscience's return on equity of -84.40% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%
Allarity Therapeutics	N/A	-152.77%	-46.50%

Yarrow Bioscience has a beta of 2.01, suggesting that its share price is 101% more volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

Yarrow Bioscience currently has a consensus price target of $58.00, indicating a potential upside of 98.02%. Allarity Therapeutics has a consensus price target of $10.25, indicating a potential upside of 747.11%. Given Allarity Therapeutics' higher possible upside, analysts plainly believe Allarity Therapeutics is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yarrow Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Yarrow Bioscience had 5 more articles in the media than Allarity Therapeutics. MarketBeat recorded 7 mentions for Yarrow Bioscience and 2 mentions for Allarity Therapeutics. Yarrow Bioscience's average media sentiment score of 0.37 beat Allarity Therapeutics' score of 0.00 indicating that Yarrow Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Yarrow Bioscience	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allarity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

83.8% of Yarrow Bioscience shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 3.0% of Yarrow Bioscience shares are owned by company insiders. Comparatively, 0.2% of Allarity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Allarity Therapeutics has lower revenue, but higher earnings than Yarrow Bioscience. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Allarity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yarrow Bioscience	$570K	137.20	-$26.48M	-$14.64	N/A
Allarity Therapeutics	$320K	60.16	-$11.23M	-$0.78	N/A

Summary

Yarrow Bioscience beats Allarity Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Allarity Therapeutics compare to XBiotech?

Allarity Therapeutics (NASDAQ:ALLR) and XBiotech (NASDAQ:XBIT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Allarity Therapeutics has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, XBiotech has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

XBiotech's return on equity of -31.62% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-152.77%	-46.50%
XBiotech	N/A	-31.62%	-30.29%

Allarity Therapeutics has higher revenue and earnings than XBiotech. Allarity Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	60.16	-$11.23M	-$0.78	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A

11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 0.2% of Allarity Therapeutics shares are owned by insiders. Comparatively, 30.8% of XBiotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Allarity Therapeutics had 1 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for Allarity Therapeutics and 1 mentions for XBiotech. Allarity Therapeutics' average media sentiment score of 0.00 equaled XBiotech'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allarity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
XBiotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Allarity Therapeutics presently has a consensus target price of $10.25, indicating a potential upside of 747.11%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Allarity Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Allarity Therapeutics beats XBiotech on 7 of the 13 factors compared between the two stocks.

How does Allarity Therapeutics compare to ALPS Group Inc Ordinary Share?

Allarity Therapeutics (NASDAQ:ALLR) and ALPS Group Inc Ordinary Share (NASDAQ:ALPS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

Allarity Therapeutics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, ALPS Group Inc Ordinary Share has a beta of -0.1, meaning that its share price is 110% less volatile than the broader market.

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-152.77%	-46.50%
ALPS Group Inc Ordinary Share	N/A	N/A	N/A

11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 27.9% of ALPS Group Inc Ordinary Share shares are owned by institutional investors. 0.2% of Allarity Therapeutics shares are owned by company insiders. Comparatively, 25.5% of ALPS Group Inc Ordinary Share shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ALPS Group Inc Ordinary Share	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ALPS Group Inc Ordinary Share has higher revenue and earnings than Allarity Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	60.16	-$11.23M	-$0.78	N/A
ALPS Group Inc Ordinary Share	$4.86M	13.70	-$2.01M	$0.33	1.21

In the previous week, Allarity Therapeutics had 2 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 2 mentions for Allarity Therapeutics and 0 mentions for ALPS Group Inc Ordinary Share. Allarity Therapeutics' average media sentiment score of 0.00 equaled ALPS Group Inc Ordinary Share'saverage media sentiment score.

Company	Overall Sentiment
Allarity Therapeutics	Neutral
ALPS Group Inc Ordinary Share	Neutral

Summary

ALPS Group Inc Ordinary Share beats Allarity Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Allarity Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALLR vs. The Competition

Export

Metric	Allarity Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$19.25M	$3.90B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-1.55	14.23	275.49	25.40
Price / Sales	60.16	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	1.98	15.45	10.46	6.33
Net Income	-$11.23M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-0.82%	-1.21%	0.59%	1.12%
1 Month Performance	-15.38%	-3.29%	-1.74%	-2.39%
1 Year Performance	-21.43%	37.74%	18.13%	5.35%

Allarity Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALLR Allarity Therapeutics	1.3943 of 5 stars	$1.21 +4.3%	$10.25 +747.1%	-21.4%	$19.25M	$320K	N/A	8	Gap Up
OKYO OKYO Pharma	2.3874 of 5 stars	$1.37 -1.9%	$5.67 +312.4%	-31.3%	$71.11M	N/A	N/A	7	Gap Down
PLRX Pliant Therapeutics	1.626 of 5 stars	$1.12 -3.0%	$3.00 +169.1%	-22.4%	$69.04M	$1.58M	N/A	90	News Coverage Positive News Gap Down
YARW Yarrow Bioscience	2.5497 of 5 stars	$25.75 +1.0%	$58.00 +125.2%	N/A	$68.61M	$570K	N/A	30
XBIT XBiotech	0.138 of 5 stars	$2.20 +0.5%	N/A	-19.5%	$67.08M	N/A	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALLR) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Allarity Therapeutics (ALLR) Competitors

ALLR vs. OKYO, PLRX, YARW, XBIT, and ALPS

How does Allarity Therapeutics compare to OKYO Pharma?

Summary

How does Allarity Therapeutics compare to Pliant Therapeutics?

Summary

How does Allarity Therapeutics compare to Yarrow Bioscience?

Summary

How does Allarity Therapeutics compare to XBiotech?

Summary

How does Allarity Therapeutics compare to ALPS Group Inc Ordinary Share?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR vs. The Competition

Allarity Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Allarity Therapeutics (ALLR) Competitors

ALLR vs. OKYO, PLRX, YARW, XBIT, and ALPS

How does Allarity Therapeutics compare to OKYO Pharma?

Which has more volatility and risk, OKYO or ALLR?

Do analysts recommend OKYO or ALLR?

Do insiders & institutionals have more ownership in OKYO or ALLR?

Does the media refer more to OKYO or ALLR?

Which has stronger earnings and valuation, OKYO or ALLR?

Is OKYO or ALLR more profitable?

Summary

How does Allarity Therapeutics compare to Pliant Therapeutics?

Does the media prefer PLRX or ALLR?

Do analysts recommend PLRX or ALLR?

Which has more risk & volatility, PLRX or ALLR?

Do insiders and institutionals have more ownership in PLRX or ALLR?

Is PLRX or ALLR more profitable?

Which has better valuation and earnings, PLRX or ALLR?

Summary

How does Allarity Therapeutics compare to Yarrow Bioscience?

Is YARW or ALLR more profitable?

Which has more volatility & risk, YARW or ALLR?

Do analysts recommend YARW or ALLR?

Does the media prefer YARW or ALLR?

Do institutionals & insiders have more ownership in YARW or ALLR?

Which has higher earnings & valuation, YARW or ALLR?

Summary

How does Allarity Therapeutics compare to XBiotech?

Which has more volatility and risk, ALLR or XBIT?

Is ALLR or XBIT more profitable?

Which has higher earnings & valuation, ALLR or XBIT?

Do institutionals and insiders believe in ALLR or XBIT?

Does the media refer more to ALLR or XBIT?

Do analysts recommend ALLR or XBIT?

Summary

How does Allarity Therapeutics compare to ALPS Group Inc Ordinary Share?

Which has more risk and volatility, ALLR or ALPS?

Is ALLR or ALPS more profitable?

Do insiders & institutionals have more ownership in ALLR or ALPS?

Do analysts prefer ALLR or ALPS?

Which has higher valuation and earnings, ALLR or ALPS?

Does the media favor ALLR or ALPS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR vs. The Competition

Allarity Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools